Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03732820
Other study ID # D081SC00001
Secondary ID 2018-002011-10
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date October 31, 2018
Est. completion date April 28, 2026

Study information

Verified date February 2024
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.


Description:

PROpel is a phase III study evaluating the efficacy, safety, and tolerability of olaparib versus placebo when given in addition to abiraterone to patients with metastatic castration-resistant prostate cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line setting). Approximately 720 patients globally were planned to be randomized in PROpel in a 1:1 ratio to treatment with either olaparib and abiraterone or placebo and abiraterone. Enrolment had completed with a total of 796 patients randomised. Following the completion of global enrolment, the China cohort will randomise approximately 108 additional patients at sites in China, also in a 1:1 ratio. Patients will receive oral treatment with olaparib 300 mg twice daily + abiraterone 1000 mg once daily or placebo twice daily + abiraterone 1000 mg once daily. Patients in both treatment groups will also receive either prednisone or prednisolone 5 mg twice daily.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 895
Est. completion date April 28, 2026
Est. primary completion date July 30, 2021
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: 1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in the study protocol. 2. Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses. 3. For inclusion in i) the optional exploratory genetic research and ii) the optional biomarker research, patients must fulfill the following criteria: - Provision of informed consent for genetic research prior to collection of sample. - Provision of informed consent for biomarker research prior to collection of sample. If a patient declines to participate in the optional exploratory genetic research or the optional biomarker research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study. 4. Patients must be =18 years of age (or =19 years of age in South Korea) at the time of signing the informed consent form. For patients enrolled in Japan who are <20 years of age, written informed consent should be obtained from the patient and from his legally acceptable representative. 5. Histologically or cytologically confirmed prostate adenocarcinoma. 6. Metastatic status defined as at least 1 documented metastatic lesion on either a bone scan or a computed tomography(CT)/ magnetic resonance imaging (MRI) scan. 7. First-line metastatic castration-resistant prostate cancer (mCRPC). 8. Ongoing androgen deprivation with gonadotropin-releasing hormone analogue or bilateral orchiectomy, with serum testosterone <50 nanograms per decilitre (ng/dL) (<2.0 nanomoles per litre (nmol/L)) within 28 days before randomisation. Patients receiving androgen deprivation therapy (ADT) at study entry should continue to do so throughout the study. 9. Candidate for abiraterone therapy with documented evidence of progressive disease. 10. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment. 11. Eastern Cooperative Oncology Group (ECOG) performance status 0-1, with no deterioration over the previous 2 weeks. 12. The participant has, in the opinion of the investigator, a life expectancy of at least 6 months. 13. Prior to randomisation, sites must confirm availability of either an archival formalin fixed, paraffin embedded (FFPE) tumour tissue sample, or a new biopsy taken during the screening window, which meets the minimum pathology and sample requirements in order to enable homologous recombination repair (HRR) status subgroup analysis of the primary endpoint radiographic progression-free survival (rPFS). If there is not written confirmation of the availability of tumour tissue prior to randomisation, the patient is not eligible for the study. 14. Male patients must use a condom during treatment and for 3 months after the last dose of olaparib+abiraterone when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential. Exclusion Criteria: 1. Has a known additional malignancy that has had progression or has required active treatment in the last 5 years. 2. Patients with myelodysplastic syndrome (MDS)/ acute myeloid leukaemia (AML) or with features suggestive of yelodysplastic syndrome (MDS)/ acute myeloid leukaemia (AML). 3. Clinically significant cardiovascular disease Association Class II-IV heart failure or cardiac ejection fraction measurement of <50% during screening as assessed by echocardiography or multigated acquisition scan. 4. Planned or scheduled cardiac surgery or percutaneous coronary intervention procedure. 5. Prior revascularisation procedure (significant coronary, carotid, or peripheral artery stenosis). 6. Uncontrolled hypertension (systolic blood pressure (BP) =160 millimeters of mercury (mmHg) or diastolic blood pressure (BP) =95 millimeters of mercury (mmHg)). 7. History of uncontrolled pituitary or adrenal dysfunction. 8. Active infection or other medical condition that would make prednisone/prednisolone use contraindicated. 9. Any chronic medical condition requiring a systemic dose of corticosteroid >10 milligrams (mg) prednisone/prednisolone per day. 10. Patients who are considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. 11. Persistent toxicities (Common Terminology Criteria for Adverse Events [CTCAEs] grade >2) caused by previous cancer therapy, excluding alopecia. 12. Patients with brain metastases. A scan to confirm the absence of brain metastases is not required. 13. Patients with spinal cord compression are excluded unless they are considered to have received definitive treatment for this and have evidence of clinically stable disease for 4 weeks. 14. Patients who are unevaluable for both bone and soft tissue progression 15. Patients who are unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication. 16. Immunocompromised patients 17. Patients with known active hepatitis infection (ie, hepatitis B or C). 18. Any previous treatment with Polyadenosine 5'diphosphoribose [poly (ADP ribose)] polymerase (PARP) inhibitor, including olaparib. 19. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment. Patients who receive palliative radiotherapy need to stop radiotherapy 1 week before randomisation. 20. Any previous exposure to a Cytochrome P450 (CYP) 17 (17a-hydroxylase/C17,20-lyase) inhibitor (eg, abiraterone, orteronel). 21. Concomitant use of known strong Cytochrome P450 (CYP) 3A inhibitors (eg, itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg, ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study treatment is 2 weeks. 22. Concomitant use of known strong Cytochrome P450 (CYP) 3A inducers (eg, phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine or St John's wort) or moderate Cytochrome P450 (CYP) 3A inducers (eg, bosentan, efavirenz or modafinil). The required period prior to starting study treatment is 5 weeks for phenobarbital and enzalutamide and 3 weeks for other agents. 23. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery. 24. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT). 25. Participation in another clinical study with an investigational product or investigational medical devices within 1 month of randomisation. 26. History of hypersensitivity to olaparib or abiraterone, any of the excipients of olaparib or abiraterone, or drugs with a similar chemical structure or class to olaparib or abiraterone. 27. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca and Merck staff and/or staff at the study site). 28. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements. 29. Previous randomisation in the present study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
olaparib
300 mg (2 x 150 milligrams (mg) tablets) twice daily
abiraterone acetate
1000 milligrams (mg) once daily

Locations

Country Name City State
Australia Research Site Box Hill
Australia Research Site Darlinghurst
Australia Research Site Greenslopes
Australia Research Site Herston
Australia Research Site Kingswood
Australia Research Site Kurralta Park
Australia Research Site St Albans
Australia Research Site Waratah
Belgium Research Site Gent
Brazil Research Site Belo Horizonte
Brazil Research Site Curitiba
Brazil Research Site Fortaleza
Brazil Research Site Porto Alegre
Brazil Research Site Rio de Janeiro
Brazil Research Site São José do Rio Preto
Brazil Research Site Sao Paulo
Brazil Research Site Sao Paulo
Canada Research Site Calgary Alberta
Canada Research Site Edmonton Alberta
Canada Research Site Greenfield Park Quebec
Canada Research Site Halifax Nova Scotia
Canada Research Site Kelowna British Columbia
Canada Research Site London Ontario
Canada Research Site Montreal Quebec
Canada Research Site Montreal Quebec
Canada Research Site Toronto Ontario
Canada Research Site Toronto Ontario
Chile Research Site Santiago
Chile Research Site Santiago
Chile Research Site Temuco
Chile Research Site Viña del Mar
Czechia Research Site Brno
Czechia Research Site Praha
Czechia Research Site Praha
Czechia Research Site Praha 5
France Research Site Angers Cedex 01
France Research Site BESANCON Cedex
France Research Site Caen Cedex 05
France Research Site Pierre Benite
France Research Site Quimper Cedex
France Research Site Vandoeuvre les Nancy
Germany Research Site Bergisch Gladbach
Germany Research Site Bremen
Germany Research Site Duisburg
Germany Research Site Freiburg im Breisgau
Germany Research Site Heinsberg
Germany Research Site Köln
Germany Research Site Mettmann
Germany Research Site Nürnberg
Germany Research Site Nürtingen
Germany Research Site Ulm
Italy Research Site Milano
Italy Research Site Milano
Italy Research Site Napoli
Italy Research Site Orbassano
Italy Research Site Pavia
Japan Research Site Bunkyo-ku
Japan Research Site Hirakata-shi
Japan Research Site Kanazawa-shi
Japan Research Site Kashihara-shi
Japan Research Site Kawagoe-shi
Japan Research Site Kita-gun
Japan Research Site Kyoto-shi
Japan Research Site Maebashi-shi
Japan Research Site Miyazaki-city
Japan Research Site Nagoya-shi
Japan Research Site Osaka-shi
Japan Research Site Osaka-shi
Japan Research Site Osakasayama-shi
Japan Research Site Sagamihara-shi
Japan Research Site Sakura-shi
Japan Research Site Shinjuku-ku
Japan Research Site Toon-shi
Japan Research Site Yokohama-shi
Korea, Republic of Research Site Daegu
Korea, Republic of Research Site Goyang-si
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Netherlands Research Site Hilversum
Netherlands Research Site Nijmegen
Netherlands Research Site Tilburg
Slovakia Research Site Bratislava
Slovakia Research Site Presov
Slovakia Research Site Sala
Slovakia Research Site Trencín
Spain Research Site Barcelona
Spain Research Site Gerona
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Malaga
Spain Research Site Sevilla
Turkey Research Site Adana
Turkey Research Site Ankara
Turkey Research Site Ankara
Turkey Research Site Istanbul
Turkey Research Site Izmir
Turkey Research Site Karsiyaka
United Kingdom Research Site Guildford
United Kingdom Research Site Manchester
United Kingdom Research Site Sheffield
United Kingdom Research Site Southampton
United Kingdom Research Site Swansea
United States Research Site Anchorage Alaska
United States Research Site Birmingham Alabama
United States Research Site Bozeman Montana
United States Research Site Brooklyn New York
United States Research Site Charleston South Carolina
United States Research Site Clovis California
United States Research Site Denver Colorado
United States Research Site Detroit Michigan
United States Research Site Durham North Carolina
United States Research Site Grand Rapids Michigan
United States Research Site Jeffersonville Indiana
United States Research Site Lisle Illinois
United States Research Site Los Angeles California
United States Research Site Los Angeles California
United States Research Site Milwaukee Wisconsin
United States Research Site Myrtle Beach South Carolina
United States Research Site New Hyde Park New York
United States Research Site New Orleans Louisiana
United States Research Site Omaha Nebraska
United States Research Site Paramus New Jersey
United States Research Site Philadelphia Pennsylvania
United States Research Site Rochester New York
United States Research Site Sacramento California
United States Research Site Saint Louis Missouri
United States Research Site San Diego California
United States Research Site Syracuse New York
United States Research Site Tucson Arizona
United States Research Site Tucson Arizona

Sponsors (2)

Lead Sponsor Collaborator
AstraZeneca Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Brazil,  Canada,  Chile,  Czechia,  France,  Germany,  Italy,  Japan,  Korea, Republic of,  Netherlands,  Slovakia,  Spain,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment An rPFS event is defined as progression determined by Response Evaluation Criteria in Solid Tumours version 1.1 [RECIST 1.1] and/or Prostate Cancer Working Group 3 [PCWG-3] or death (by any cause in the absence of progression), regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy prior to progression.
Per RECIST v1.1, progression is defined as the sum of TLs has a 20% and absolute = 5mm increase from nadir, and/or unequivocal progression in any non target lesions, and/or any new lesion identified.
Per PCWG3, progression on a bone scan is defined as 2 or more new lesions observed from the first visit after baseline compared to baseline, or from all other visits compared to first visit after baseline. A confirmatory scan is required.
Assessed from date of randomisation to data cut off (DCO1): 30Jul2021 (Approx. 2 years 9 months)
Secondary Number of Participants With Overall Survival (OS) Event An OS event is defined as death by any cause, regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy. Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months). DCO3 is the final data cut-off for the OS analysis and therefore no further updates will be made.
Secondary Number of Participants With Time to First Subsequent Anticancer Therapy or Death (TFST) Event A TFST (excluding radiotherapy) event is defined as the start of the first subsequent anticancer therapy after discontinuation of randomised treatment or death from any cause. Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Secondary Number of Participants With Time to Pain Progression (TTPP) Event A TTPP event is defined as pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 (range 0-10, a higher score indicates worse pain) and opiate analgesic use (Analgesic quantification algorithm [AQA] score, range 0-7, a higher score indicates increased opioid use). For patients who are asymptomatic at baseline (average worst pain score of 0 and not taking opioids): A =2 point change from baseline in average (4-7 days) worst pain score observed at 2 consecutive visits or initiation of opioid use; For patients who are symptomatic at baseline (average worst pain score >0 and/or receiving opioids): A =2 point change from baseline in average (4-7 days) worst pain score observed at 2 consecutive visits and an average worst pain score =4, and no decrease in average opioid use (=1-point decrease in AQA score from a starting value of =2), or increase in opioid use (=1-point increase, or =2-point increase if the starting value is 0) at 2 consecutive follow-up visits. Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Secondary Number of Participants With Opiate Use An event for opiate use is defined as the first opiate use for cancer related pain. Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Secondary Number of Participants With First Symptomatic Skeletal Related Event (SSRE) An SSRE event is defined as the first sympomatic skeletal-related event defined by
Use of radiation therapy to prevent or relieve skeletal symptoms.
Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral).
Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Secondary Number of Participants With Second Progression or Death (PFS2) Event An event for PFS2 is defined as the second progression on next-line anticancer therapy or death, whichever occurs earlier. Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Secondary Brief Pain Inventory-Short Form (BPI-SF) The BPI-SF is a validated, 15-item domain-specific instrument designed to assess the severity of pain and the impact/interference of pain on daily functions. BPI-SF worst pain, pain severity and pain interference score changes can be a minimum of -10 and a maximum of 10. A negative change from baseline value indicates improvement. Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Secondary Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P) Functional Assessment of Cancer Therapy-Prostate Cancer (FACT-P) total score and Functional Assessment of Cancer Therapy-General (FACT-G) total score.
Total FACT-P score is the sum of Physical Well-being (PWB), Social Well-being (SWB), Emotional Well-being (EWB), Functional Well-being (FWB) and Prostate cancer subscale (PCS). FACT-P total score change from baseline values can be a minimum of -156 and a maximum of 156. A positive value indicates improvement.
FACT-G total score is the sum of PWB, SWB, EWB and FWB. FACT-G Total score change from baseline values can be a minimum of -108 and a maximum of 108. A positive value indicates improvement.
Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
See also
  Status Clinical Trial Phase
Recruiting NCT04986423 - ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT05489991 - A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Phase 1/Phase 2
Active, not recruiting NCT05521412 - EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T Phase 1/Phase 2
Terminated NCT04556617 - PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 1/Phase 2
Completed NCT02125357 - Sequencing Abiraterone and Enzalutamide in mCRPC Phase 2
Recruiting NCT06052306 - A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) Phase 1
Recruiting NCT05917470 - A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. Phase 1/Phase 2
Recruiting NCT05519449 - Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) Phase 1
Terminated NCT05301062 - A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
Recruiting NCT05383079 - Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT04060394 - Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Phase 1/Phase 2
Completed NCT01942837 - Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer Phase 2
Recruiting NCT05458544 - [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application Phase 1/Phase 2
Withdrawn NCT04879589 - Phase 1 Study of ATRS-2002 in Healthy Male Adults Phase 1
Recruiting NCT03230734 - Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer Phase 2
Recruiting NCT05116579 - Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
Recruiting NCT05005728 - XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05762536 - Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC Phase 2
Recruiting NCT06067841 - A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer Phase 1